华法林,临床注释-2,变异和临床注释数据

华法林

临床注释ID

981238341

药物名称(英)

warfarin

变异单倍型

CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*11

基因

CYP2C9

证据级别

1A

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Dosage

表现型类别

剂量

分数

675.75

PMID计数

130

计数的证据

215

表现型

心血管疾病

表现型(英)

Cardiovascular Diseases

最新日期

2021/10/5 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/981238341

专业人口(英)

Pediatric

专业人口

儿科

临床等位基因

id	等位基因	注释文本
952	*11	The CYP2C911 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C911 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.
951	*8	The CYP2C98 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C98 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.
950	*6	The CYP2C96 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C96 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.
949	*5	The CYP2C95 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C95 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.
948	*4	The CYP2C94 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C94 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. Other genetic and clinical factors may also influence warfarin dose.
947	*3	The CYP2C93 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C93 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.
946	*2	The CYP2C92 allele is assigned as a decreased function allele by CPIC. Patients carrying the CYP2C92 allele in combination with a normal, decreased, or no function allele may require a lower dose of warfarin as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence warfarin dose.
945	*1	The CYP2C91 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C91 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.

临床证据

id	证据的ID	总结
2848	PA166104949	Annotation of CPIC Guideline for warfarin and CYP2C9, CYP4F2, VKORC1
2492	827783868	CYP2C9 3/3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 1/1.
2491	827919407	CYP2C9 8 is associated with decreased in vitro intrinsic clearance of S-warfarin with the cDNA-expressed R150H protein when treated with warfarin as compared to CYP2C9 1/*1.
2490	1449005488	Allele G is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele C.
2489	1448109681	Allele C is associated with dose of warfarin as compared to allele G.
2488	827864554	Allele G is associated with decreased dose of warfarin as compared to allele C.
2487	608431793	Allele G is associated with decreased dose of warfarin as compared to allele C.
2486	982036966	Allele G is associated with decreased dose of warfarin as compared to allele C.
2485	982036951	Allele G is associated with decreased dose of warfarin as compared to allele C.
2484	982036958	Allele C is associated with decreased dose of warfarin as compared to allele T.
2483	982036710	Allele C is associated with decreased dose of warfarin as compared to allele T.
2482	982034970	Genotype CT is associated with decreased dose of warfarin as compared to genotype TT.
2481	1449269204	Allele C is associated with dose of warfarin as compared to allele A.
2480	1449258301	Allele C is associated with decreased dose of warfarin as compared to allele A.
2479	1449192290	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2478	1449190935	Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele A.
2477	1449005213	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2476	1449005162	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2475	1448624168	Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.
2474	1448615546	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.
2473	1448431507	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.
2472	1448112396	Genotype CC is associated with decreased clearance of warfarin as compared to genotypes AA + AC.
2471	1448109677	Allele A is associated with dose of warfarin as compared to allele C.
2470	1447519932	Allele C is associated with decreased dose of warfarin as compared to allele A.
2469	1446765922	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2468	1444694693	Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AC.
2467	1184756158	Allele A is associated with increased dose of warfarin in people with heart valve replacement as compared to allele C.
2466	1184511620	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2465	1184482810	Genotypes AA + AC is associated with increased dose of warfarin as compared to genotype CC.
2464	1184169096	Genotype AA is associated with increased dose of warfarin in people with Heart Valve Diseases as compared to genotype AC.
2463	1183700614	Genotypes AC + CC is associated with decreased dose of warfarin in men as compared to genotype AA.
2462	1183699320	Allele C is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele A.
2461	1183699129	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2460	827864562	Allele C is associated with decreased dose of warfarin as compared to allele A.
2459	769182559	Genotype AA is associated with increased dose of warfarin as compared to genotypes AC + CC.
2458	655387562	Allele C is associated with decreased dose of warfarin.
2457	608431732	Allele C is associated with decreased dose of warfarin.
2456	655388494	Allele C is associated with decreased dose of warfarin as compared to allele A.
2455	827845798	Genotype AC is associated with decreased dose of warfarin in people with an international normalized ratio (INR) of 2.0-3.0 as compared to genotype AA.
2454	827823825	Allele C is associated with decreased dose of warfarin as compared to allele A.
2453	827814740	Allele C is associated with decreased dose of warfarin as compared to allele A.
2452	827661941	Genotypes AC + CC are associated with decreased dose of warfarin as compared to genotype AA.
2451	827658659	Genotype AC is associated with decreased dose of warfarin as compared to genotype AA.
2450	827641903	Allele C is associated with decreased dose of warfarin as compared to allele A.
2449	827602228	Allele C is associated with decreased dose of warfarin as compared to allele A.
2448	982037860	Allele C is associated with decreased dose of warfarin as compared to allele A.
2447	982036874	Allele C is associated with decreased dose of warfarin as compared to allele A.
2446	982036698	Allele C is associated with decreased dose of warfarin as compared to allele A.
2445	982035694	Genotype AC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA.
2444	982033533	Allele C is associated with decreased dose of warfarin as compared to allele A.
2443	982033269	Allele C is associated with decreased dose of warfarin as compared to allele A.
2442	982033206	Genotype AC is associated with decreased in vivo metabolism of (S)-warfarin but not (R)-warfarin when treated with warfarin as compared to genotype AA.
2441	982032955	Allele C is associated with decreased dose of warfarin as compared to allele A.
2440	1448109696	Allele C is associated with dose of warfarin as compared to allele T.
2439	608431789	Allele T is associated with decreased dose of warfarin as compared to allele C.
2438	982043421	Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC.
2437	982036973	Allele T is associated with decreased dose of warfarin as compared to allele C.
2436	1449005482	Allele del is associated with decreased dose of warfarin in Pulmonary Embolism as compared to allele A.
2435	1448109688	Allele A is associated with dose of warfarin as compared to allele del.
2434	608431785	Allele del is associated with decreased dose of warfarin.
2433	827864548	Allele A is associated with decreased dose of warfarin as compared to allele G.
2432	608431781	Allele A is associated with decreased dose of warfarin as compared to allele G.
2431	827787814	Allele A is associated with warfarin variability when treated with warfarin as compared to allele G.
2430	981785989	Allele A is associated with decreased median weekly warfarin dose requirements when treated with warfarin as compared to allele G.
2429	981785769	Allele A is associated with decreased S-warfarin clearance when treated with warfarin as compared to allele G.
2428	1449269199	Allele T is associated with dose of warfarin as compared to allele C.
2427	1449262882	Allele T is associated with dose of warfarin in people with Cardiovascular Diseases as compared to allele C.
2426	1449192282	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.
2425	1448112390	Genotype TT is associated with decreased clearance of warfarin as compared to genotypes CC + CT.
2424	1448109670	Allele C is associated with dose of warfarin as compared to allele T.
2423	1183701883	Allele T is associated with decreased metabolism of warfarin as compared to allele C.
2422	1183699325	Allele T is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to allele C.
2421	827864546	Allele T is associated with decreased dose of warfarin as compared to allele C.
2420	655387565	Allele T is associated with decreased dose of warfarin.
2419	608431758	Allele T is associated with decreased dose of warfarin.
2418	827823816	Allele T is associated with decreased dose of warfarin as compared to allele C.
2417	827814765	Allele T is not associated with decreased dose of acenocoumarol or warfarin as compared to allele C.
2416	827657784	Genotype CT is associated with decreased dose of warfarin as compared to genotype CC.
2415	827641894	Allele T is associated with decreased dose of warfarin as compared to allele C.
2414	827602050	Allele T is associated with decreased dose of warfarin as compared to allele C.
2413	982038144	Allele T is associated with decreased dose of warfarin as compared to allele C.
2412	982037879	Allele T is associated with decreased dose of warfarin as compared to allele C.
2411	982036901	Allele T is associated with decreased dose of warfarin as compared to allele C.
2410	982036689	Allele T is associated with decreased dose of warfarin as compared to allele C.
2409	982033561	Allele T is associated with decreased dose of warfarin as compared to allele C.
2408	982033292	Allele T is associated with decreased dose of warfarin as compared to allele C.
2407	1451221905	Genotype AC is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to genotype AA.
2406	1449164047	CYP2C9 normal metabolizers are associated with increased dose of warfarin as compared to CYP2C9 poor metabolizers and intermediate metabolizers.
2405	PA166104776	Annotation of FDA Label for warfarin and CYP2C9, PROC, PROS1, VKORC1
2404	PA166182842	Annotation of DPWG Guideline for warfarin and CYP2C9
2136	1184472455	CYP2C9 3 + 5 + 2 + 1 is associated with dose of warfarin.
2135	1184471902	CYP2C9 1/3 is associated with decreased Unbound oral clearance for S-warfarin when treated with warfarin in children as compared to CYP2C9 1/1.
2134	1183701586	CYP2C9 6/6 is associated with decreased dose of warfarin.
2133	1183701573	CYP2C9 1/3 is associated with decreased dose of warfarin.
2132	1183701565	CYP2C9 3 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2131	1183701549	CYP2C9 2 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2130	1183701514	CYP2C9 1/3 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 1/1.
2129	1183701501	CYP2C9 2 is associated with decreased dose of warfarin in people with venous thromboembolism as compared to CYP2C9 1.
2128	1183701419	CYP2C9 11 + 2 + 3 + 5 + 6 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2127	1183701320	CYP2C9 1/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2126	1183701311	CYP2C9 1/2 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2125	1183701135	CYP2C9 3/3 is associated with increased risk of Hemorrhage when treated with warfarin.
2124	1183701116	CYP2C9 *3 is associated with decreased dose of warfarin.
2123	1183701108	CYP2C9 *2 is associated with decreased dose of warfarin.
2122	1183700910	CYP2C9 8/8 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2121	1183700824	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 + 3/3 is associated with decreased clearance of warfarin as compared to CYP2C9 1/1.
2120	1183700775	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2119	1183700748	CYP2C9 3 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2118	1183700730	CYP2C9 2 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2117	1183700669	CYP2C9 1/3 + 2/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2116	1183700648	CYP2C9 1/2 + 2/2 + 2/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2115	1183700587	CYP2C9 1/3 + 3/3 is associated with decreased dose of warfarin in men as compared to CYP2C9 1/1.
2114	1183700166	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 + 3/3 is associated with increased time to achieve stable dose when treated with warfarin as compared to CYP2C9 1/1.
2113	1183700123	CYP2C9 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2112	1183700115	CYP2C9 2/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2111	1183700106	CYP2C9 2/2 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2110	1183700096	CYP2C9 1/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2109	1183700066	CYP2C9 1/2 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2108	1183699310	CYP2C9 2 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 1.
2107	1183699285	CYP2C9 3 is associated with decreased dose of warfarin in people with total knee or hip arthroplasty as compared to CYP2C9 1.
2106	1183699114	CYP2C9 1/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
2105	1183697679	CYP2C9 2 + 3 are associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 *1.
2104	1183697100	CYP2C9 2 + 3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.
2103	982047968	CYP2C9 2 + 3 are associated with dose of warfarin in children as compared to CYP2C9 *1.
2102	982047415	CYP2C9 1/1 is associated with increased dose of warfarin in children as compared to CYP2C9 2/3.
2101	982047409	CYP2C9 1/1 is associated with increased dose of warfarin in children as compared to CYP2C9 2/2.
2100	982047403	CYP2C9 1/1 is associated with increased dose of warfarin in children as compared to CYP2C9 1/2.
2099	982047396	CYP2C9 1/1 is associated with increased dose of warfarin in children as compared to CYP2C9 1/3.
2098	982046140	CYP2C9 3 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 1.
2097	982046133	CYP2C9 2 is associated with decreased warfarin dose and increased risk of over-anticoagulation when treated with warfarin as compared to CYP2C9 1.
2096	982045885	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2095	982045852	CYP2C9 2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2094	982045728	CYP2C9 1/3 is associated with decreased warfarin dose in Korean patients with mechanical heart valve replacement since day 7 of warfarin therapy when treated with warfarin as compared to CYP2C9 1/1.
2093	982044655	CYP2C9 1/3 is associated with decreased dose of warfarin in patients with heart valve replacement when treated with warfarin as compared to CYP2C9 1/1.
2092	982044620	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2091	982044381	CYP2C9 1/3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1/1.
2090	982044343	CYP2C9 2 is not associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2089	982044336	CYP2C9 3 is associated with decreased warfarin dose after adjustment for VKORC11173 when treated with warfarin as compared to CYP2C9 *1.
2088	982043935	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2087	982043928	CYP2C9 2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2086	982043919	CYP2C9 3 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2085	982043913	CYP2C9 2 is associated with decreased dose of warfarin as compared to CYP2C9 1.
2084	982043863	CYP2C9 3 is associated with decreased warfarin dose (40% lower) when treated with warfarin as compared to CYP2C9 1.
2083	982043785	CYP2C9 1/3 is associated with decreased unbound oral clearance for S-warfarin when treated with warfarin as compared to CYP2C9 1/1.
2082	982043654	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2081	982043575	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2080	982043569	CYP2C9 2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2079	982043530	CYP2C9 1/3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1/1.
2078	982043415	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2077	982043409	CYP2C9 2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2076	982043064	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2075	982043050	CYP2C9 2 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2074	982040707	CYP2C9 3 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1.
2073	982037661	CYP2C9 1/3 + 1/4 is associated with decreased warfarin dose when treated with warfarin as compared to CYP2C9 1/1.
2072	982037353	CYP2C9 1/2 + 1/3 is associated with decreased dose of warfarin when treated with warfarin as compared to CYP2C9 1/1.
2071	981858924	CYP2C9 1/2 + 1/3 is not associated with dose of warfarin in children as compared to CYP2C9 1/1.
2070	981754835	CYP2C9 1/1 is associated with increased dose of warfarin as compared to CYP2C9 2/2 + 2/3 + 3/3 + 1/2 + 1/3.
2069	981505330	CYP2C9 3 is associated with decreased warfarin dose requirement when treated with warfarin as compared to CYP2C9 1/*1.
2068	981505317	CYP2C9 2 is associated with lower warfarin dose requirement when treated with warfarin as compared to CYP2C9 1/*1.
2067	827919910	CYP2C9 *2 is associated with decreased dose of warfarin.
2066	827919905	CYP2C9 *2 is not associated with decreased dose of warfarin when treated with simvastatin and warfarin.
2065	827919924	CYP2C9 *3 is associated with decreased dose of warfarin.
2064	827919897	CYP2C9 *3 is associated with decreased dose of warfarin when treated with simvastatin and warfarin.
2063	827919392	CYP2C9 8 is associated with decreased unbound oral clearance of S-warfarin and lower R- to S-warfarin plasma concentration ratio when treated with warfarin as compared to CYP2C9 1/*1.
2062	827863698	CYP2C9 2 is associated with decreased clearance of warfarin as compared to CYP2C9 1.
2061	827863693	CYP2C9 3 is associated with decreased clearance of warfarin as compared to CYP2C9 1.
2060	827783860	CYP2C9 2/2 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 1/1.
2059	827807419	CYP2C9 1/1 is associated with increased dose of warfarin.
2058	827783312	CYP2C9 3/3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 1/1.
2057	827783863	CYP2C9 2/3 is associated with decreased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP2C9 1/1.
2056	981483998	CYP2C9 1/3 + 3/3 is associated with decreased dose of warfarin in people with mechanical heart valve replacement as compared to CYP2C9 1/1.
2055	981345093	CYP2C9 *3 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.
2054	981345061	CYP2C9 *2 is associated with decreased dose of warfarin in people with Cardiovascular Diseases.
2053	981344716	CYP2C9 3 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 1.
2052	981344709	CYP2C9 2 is associated with decreased clearance of warfarin in people with Cardiovascular Diseases as compared to CYP2C9 1.
2051	978614436	CYP2C9 *3 is associated with dose of warfarin.
2050	978614420	CYP2C9 *8 is associated with dose of warfarin.
2049	978614428	CYP2C9 *2 is associated with dose of warfarin.
2048	827925130	CYP2C9 1/3 is associated with decreased dose of warfarin in people with Thromboembolism as compared to CYP2C9 1/1.
1727	982045974	CYP2C9 1/3 + 3/3 are associated with decreased warfarin dose in Japanese patients when treated with warfarin as compared to CYP2C9 1/1.
1726	1451516060	CYP2C9 2 + 3 are not associated with dose of phenprocoumon or warfarin as compared to CYP2C9 *1.
1725	1451130680	CYP2C9 2 + 3 are associated with decreased dose of warfarin as compared to CYP2C9 *1.
1724	1451120160	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 + 3/3 are associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1723	1183689399	CYP2C9 2 + 3 is associated with decreased dose of warfarin as compared to CYP2C9 *1.
1722	1448573256	CYP2C9 2 + 3 + 5 + 8 + 11 are associated with decreased dose of warfarin as compared to CYP2C9 1/*1.
1721	1448269030	CYP2C9 1/1 is associated with increased dose of warfarin as compared to CYP2C9 1/3.
1720	1448268043	CYP2C9 1/3 is associated with decreased dose of warfarin in people with Atrial Fibrillation as compared to CYP2C9 1/1.
1719	1448267984	CYP2C9 1/3 is associated with decreased dose of warfarin in people with Atrial Fibrillation.
1718	1447682605	CYP2C9 2 + 3 + 8 are associated with decreased dose of warfarin as compared to CYP2C9 1.
1717	1447519652	CYP2C9 2 + 3 + 5 + 6 + 11 are associated with decreased dose of warfarin as compared to CYP2C9 1/*1.
1716	1445296737	CYP2C9 5 + 6 + 11 are associated with decreased dose of warfarin as compared to CYP2C9 1/*1.
1715	1444695840	CYP2C9 1/8 + 8/8 are associated with decreased clearance of warfarin as compared to CYP2C9 1/1.
1714	1185235722	CYP2C9 1/2 + 1/3 + 2/3 is associated with decreased dose of warfarin in children as compared to CYP2C9 1/1.
1713	1184748897	CYP2C9 *3 is associated with decreased dose of warfarin.
1712	1184654401	CYP2C9 1/2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 1/1.
1711	1184654392	CYP2C9 1/3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 1/1.
1710	1184654383	CYP2C9 2/2 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 1/1.
1709	1184654374	CYP2C9 2/3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 1/1.
1708	1184654356	CYP2C9 3/3 is associated with decreased dose of warfarin in children with Heart Diseases as compared to CYP2C9 1/1.
1707	1184511945	CYP2C9 1/1 (assigned as normal metabolizers phenotype) is associated with increased dose of warfarin in healthy individuals as compared to CYP2C9 1/2 + 1/3 + 1/8 + 2/3 + 2/2 (assigned as poor metabolizers and intermediate metabolizers phenotype) .
1706	1184511561	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1705	1184510322	CYP2C9 1/2 + 1/3 + 2/2 + 2/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1704	1184510278	CYP2C9 2 + 6 + 5 + 11 is associated with decreased dose of warfarin as compared to CYP2C9 1/1 + 1/8 + 1/9 + 9/9.
1703	1184510263	CYP2C9 2 + 6 + 5 + 11 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1702	1184510232	CYP2C9 3/13 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1701	1184510172	CYP2C9 1/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1700	1184510108	CYP2C9 1/2 + 1/3 + 2/3 + 2/2 + 1/5 + 2/5 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1699	1184510026	CYP2C9 3 is associated with decreased dose of warfarin as compared to CYP2C9 1.
1698	1184509852	CYP2C9 2/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1697	1184483798	CYP2C9 1/3 + 3/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1696	1184483457	CYP2C9 3 is associated with decreased dose of warfarin as compared to CYP2C9 1.
1695	1184482762	CYP2C9 3/3 + 1/3 is associated with decreased dose of warfarin as compared to CYP2C9 1/1.
1694	1184473587	CYP2C9 2 is associated with decreased dose of warfarin in children as compared to CYP2C9 1.
1693	1184472866	CYP2C9 1/2 is associated with decreased dose of warfarin in children as compared to CYP2C9 1/1.
1692	1184472857	CYP2C9 1/3 is associated with decreased dose of warfarin in children as compared to CYP2C9 1/1.

临床病史

id	类型	评论
672	Update	Consolidated multiple VAs from same publication
671	Update	CA score added as part of scoring system release. LOE assigned following curator review.
670	Update	added guideline and label as evidence, updated text
669	Update	Minor edit to change "another normal" into "a normal" in decreased/no function allele descriptions.
668	Update	update allele texts
667	Update	Added PMID 31653973 to evidence
666	Update	Added PMID 31395958 to evidence
665	Update

最新招商产品更多>>